MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/cbf.3692

Медицинская библиотека · Cell biochemistry and function · 2022

Mammalian target of rapamycin (mTOR) signaling pathway and traumatic brain injury: A novel insight into targeted therapy.

Movahedpour Ahmad, Vakili Omid, Khalifeh Masoomeh, Mousavi Pegah, Mahmoodzadeh Amir, Taheri-Anganeh Mortaza, Razmeh Saeed, Shabaninejad Zahra, Yousefi Fatemeh, Behrouj Hamid, Ghasemi Hassan, Khatami Seyyed Hossein

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Traumatic brain injury (TBI) is one of the most concerning health issues in which the normal brain function may be disrupted as a result of a blow, bump, or jolt to the head. Loss of consciousness, amnesia, focal neurological defects, alteration in mental state, and destructive diseases of the nervous system such as cognitive impairment, Parkinson's, and Alzheimer's disease. Parkinson's disease is a chronic progressive neurodegenerative disorder, characterized by the early loss of striatal dopaminergic neurons. TBI is a major risk factor for Parkinson's disease. Existing therapeutic approaches have not been often effective, indicating the necessity of discovering more efficient therapeutic targets. The mammalian target of rapamycin (mTOR) signaling pathway responds to different environmental cues to modulate a large number of cellular processes such as cell proliferation, survival, protein synthesis, autophagy, and cell metabolism. Moreover, mTOR has been reported to affect the regeneration of the injured nerves throughout the central nervous system (CNS). In this context, recent evaluations have revealed that mTOR inhibitors could be potential targets to defeat a group of neurological disorders, and thus, a number of clinical trials are investigating their efficacy in treating dementia, autism, epilepsy, stroke, and brain injury, as irritating neurological defects. The current review describes the interplay between mTOR signaling and major CNS-related disorders (esp. neurodegenerative diseases), as well as the mTOR signaling-TBI relationship. It also aims to discuss the promising therapeutic capacities of mTOR inhibitors during the TBI.

Для цитирования: Movahedpour Ahmad, Vakili Omid, Khalifeh Masoomeh, Mousavi Pegah, Mahmoodzadeh Amir, Taheri-Anganeh Mortaza, Razmeh Saeed, Shabaninejad Zahra, Yousefi Fatemeh, Behrouj Hamid, Ghasemi Hassan, Khatami Seyyed Hossein. Mammalian target of rapamycin (mTOR) signaling pathway and traumatic brain injury: A novel insight into targeted therapy.. Cell biochemistry and function. 2022. DOI: 10.1002/cbf.3692.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.